Group 1 - The chairman of Wantai Biological Pharmacy (603392), Qiu Zixin, plans to reduce his holdings by no more than 5 million shares, raising concerns about the company's strategic stability following the resignation of the actual controller, Zhong Shanshan, as chairman [1] - The vaccine industry is facing performance pressure, with Wantai Biological, a leader in HPV vaccines, impacted by price reductions from centralized procurement and increased competition [1] Group 2 - Recently, Wantai Biological's stock has shown weak performance, closing at 41.34 yuan on February 11, 2026, with a year-to-date decline of 8.01% [2] - Trading volume has shrunk, indicating a lack of market activity, and there is a net outflow of main funds [2] Group 3 - Institutional views on Wantai Biological are neutral, with profit forecasts indicating a potential net profit growth by 2025, although the current price-to-earnings ratio is negative [3] - Market attention is focused on the rollout progress of the nine-valent vaccine and the potential pressure on stock prices from the reduction plan [3]

Group 1 - The company expects a net profit attributable to shareholders of the parent company to be between -4.1 billion and -3.3 billion yuan for the year 2025, indicating a loss compared to the same period last year [1] - The decline in performance is primarily due to the vaccine sector, which is under pressure from domestic vaccine procurement policies, industry competition, and consumer hesitancy, leading to significant decreases in both revenue and profit [1] - The company faces severe challenges on both the revenue and production fronts, particularly with its bivalent HPV vaccine, which is adversely affected by the market presence of Merck's nine-valent HPV vaccine, substantial government procurement price cuts, and insufficient consumer demand [1] Group 2 - The company is actively addressing the adverse effects of the bivalent HPV vaccine by exploring international markets and accelerating the research and development of innovative products, achieving some success [1] - In the international market, the revenue from the bivalent HPV vaccine is expected to experience exponential growth by 2025, while the first innovative product, the nine-valent HPV vaccine, has successfully launched domestically [1] - As of the end of the reporting period, the nine-valent HPV vaccine has completed market access in 27 provinces and is rapidly expanding coverage across over 30,000 points of vaccination, aiming to increase vaccination rates [1]

Core Viewpoint - WanTai Biologics (603392.SH) reported a significant decline in performance, with a 91.49% drop in net profit for 2024, attributed to challenges in the vaccine sector, including competition and government procurement impacts [1][2][9]. Financial Performance - For 2024, WanTai Biologics reported total revenue of 2.245 billion yuan, a decrease of 59.25% compared to 2023, and a net profit of 106 million yuan, down 91.49% year-on-year [2][3]. - The company recorded a non-recurring net profit of -186 million yuan, reflecting a change of -117.29% year-on-year [2][3]. - In the first quarter of 2025, the company continued to experience a downward trend, with revenue of 401 million yuan, a decline of 4.76%, and a net loss of 52.78 million yuan, marking a 141.98% decrease year-on-year [2][3]. Vaccine Sector Challenges - The decline in performance is primarily due to the vaccine segment facing market adjustments, government procurement pressures, and competition from domestic rivals [9][20]. - The price of the company's bivalent HPV vaccine has been under pressure, with the bidding price range dropping from 329-344 yuan per bottle in 2020-2022 to 63-344 yuan in 2024 [20][21]. - The company’s vaccine sales have significantly decreased, with inventory levels showing a substantial drop in production and sales compared to previous years [24][25]. Clinical Development and Market Position - WanTai Biologics is advancing its nine-valent HPV vaccine, which is currently in Phase III clinical trials, with plans for commercialization pending regulatory approval [16][19]. - The company has developed the first domestic bivalent HPV vaccine, which has gained market access in China and 21 other countries [9][12]. - The competitive landscape is intensifying, with other companies like Watson Bio also entering the HPV vaccine market, further impacting WanTai's market share [20][19]. Future Outlook - The company is focusing on its in vitro diagnostic business, which has shown more stability compared to the vaccine sector, and has appointed a new general manager with extensive experience in diagnostics [25].

Core Insights - Wantaibio (603392) reported a significant decline in revenue and net profit for 2024, with revenue at 2.245 billion yuan, down 59.25% year-on-year, and net profit at 106 million yuan, down 91.49% year-on-year, marking the lowest figures since the company went public five years ago [1][2] Revenue Breakdown - The company's revenue is primarily derived from two sectors: in vitro diagnostics and vaccines. The vaccine segment has seen a drastic decline due to market adjustments, government procurement policies, and the expansion of the target population for the nine-valent HPV vaccine [2][3] - In 2024, the vaccine segment generated revenue of 606 million yuan, a decrease of 84.69% year-on-year, with a gross margin reduction of 21.17% [2] - Vaccine production volume in 2024 was 10.5932 million doses, down 64.66% year-on-year, while sales volume was 9.0492 million doses, down 42.40% year-on-year [2] Historical Performance - Wantaibio's revenue from 2020 to 2023 was as follows: 2.354 billion yuan, 5.750 billion yuan, 11.19 billion yuan, and 5.511 billion yuan, respectively. Net profits for the same years were 1.118 billion yuan, 2.021 billion yuan, 4.736 billion yuan, and 1.248 billion yuan [2][3] - The vaccine segment was a major revenue driver, contributing significantly to the company's peak performance in 2022, where total revenue reached 11.185 billion yuan and net profit was 4.736 billion yuan, with vaccines accounting for 75.93% of total revenue [3] Competitive Landscape - The nine-valent HPV vaccine faces intense competition, with market demand slowing and other companies advancing their research rapidly. The domestic market for HPV vaccines is experiencing price wars due to government procurement policies [4][5] - Wantaibio's nine-valent HPV vaccine application was accepted on August 26, 2024, making it the first domestic nine-valent HPV vaccine to apply for market approval [4][6] - Other companies, such as Watson Bio and others, are also developing nine-valent HPV vaccines, with some expected to submit their applications for approval in the coming years, posing a potential threat to Wantaibio's market position [5][6]